HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results
Key Highlights
- ➤Nine-month revenue reached $6.7 million, versus $27,222 in 2025
- ➤HCW9302 Phase 1 readout and Recommended Phase 2 Dose expected Q1 2027
- ➤Up to $10.0 million debt financing secured, including $3.0 million received
- ➤Nine-month net loss narrowed to $5.0 million from $8.7 million
- ➤FDA provided guidance for HCW11-018b IND application planned for first half 2027
Expert Statements
Hing C. Wong, Founder and Chief Executive Officer of HCW Biologics
“Progress continues steadily for our clinical study evaluating HCW9302 in alopecia areata, and we are encouraged by results in humans that are consistent with our preclinical studies. We have the support of strong clinical sites who share our passion for developing breakthrough immunotherapeutics. With the addition of a third clinical site, we are hopeful that patient enrollment will maintain a good momentum as we come to the end of the Phase 1 clinical study. We are also excited about the great progress we have made with the molecules we have constructed using our TRBC platform, especially our lead T-cell engager, HCW11-018b, and our lead second-generation immune-checkpoint inhibitor, HCW11-040, which have the potential of revolutionizing treatment for solid tumors and senescence-associated diseases.”
MIRAMAR, Fla., Nov. 16, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and nine months ended September 30, 2026.
The Company featured two of its preclinical, non-Fc TRBC molecules at the 41(st) Annual Meeting of the Society for Immunotherapy of Cancer (“SITC2026”) which took place from November 4 – 8, 2026 in Phoenix, Arizona. In addition, the Company showcased the uniqueness of its TRBC platform to create novel multivalent non-Fc fusion molecules for solid tumor and senescence-associated diseases therapies.
Get started
Create a free account to read the full story.
